Evidence of b4GalT in prostatic cancer samples is found by detection of Galβ1,4GlcNAc (Type II) structure with the Erithrina cristagalli lectin (ECL) in PSA from prostate cancer serum and PSA from LNCaP medium as compared to seminal plasma (normal control) [25]. This evidence concerns the gene B4GALNT2 and prostate carcinoma.